IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Little is known about mode of death after acute heart failure (AHF) hospitalization. In the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant form of human relaxin-2, reduced post-discharge mortality at 180 days in selected patients with AHF.

Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study

METRA, Marco
2014-01-01

Abstract

Little is known about mode of death after acute heart failure (AHF) hospitalization. In the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant form of human relaxin-2, reduced post-discharge mortality at 180 days in selected patients with AHF.
2014
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
sì
2-s2.0-84908130787
WOS:000343470400009
Esperti anonimi
Inglese
64
15
1591
1598
8
25301463
cause of death; heart failure; relaxin; sudden cardiac death; Acute Disease; Aged; Cause of Death; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Injections, Intravenous; Male; Prospective Studies; Recombinant Proteins; Relaxin; Survival Rate; Treatment Outcome
sì
15
info:eu-repo/semantics/article
262
Felker, G. Michael; Teerlink, John R; Butler, Javed; Hernandez, Adrian F; Miller, Alan B; Cotter, Gad; Davison, Beth A; Filippatos, Gerasimos; Greenbe...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/457682
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 64
  • ???jsp.display-item.citation.isi??? 57
social impact